证券代码：600252 证券简称：中恒集团 公告编号：临 2025-88 广西梧州中恒集团股份有限公司 第十届董事会第三十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）第十 届董事会第三十二次会议通知和议案材料于 2025 年 10 月 24 日以电子邮件的方式 发出，会议于 2025 年 10 月 30 日以现场结合通讯方式在广西南宁市江南区高岭路 100 号办公楼会议室召开，公司董事长杨金海先生以现场方式出席并主持会议。 会议应当出席董事 8 人，实际出席会议董事 8 人，其中，董事王海润先生出席现 场，其他董事以通讯方式出席。会议的召集和召开符合《公司法》《公司章程》 和《公司董事会议事规则》的有关规定。 二、董事会会议审议情况 会议审议并以记名投票方式表决通过以下议案及事项： （一）会议审议通过《广西梧州中恒集团股份有限公司关于增补董事会专门 委员会成员的议案》； 根据《公司法》《公司章程》以及董事会各专门委员会议 ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2025-91 广西梧州中恒集团股份有限公司 关于政府收储控股孙公司土地进展的更正公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、《关于政府收储控股孙公司土地的进展公告》（公告编号：临 2025-87） 更正前： 目前，肇庆高新区土储中心累计支付收储补偿价款及欠付款本金的利息共计 433,508,531.20 元，其尚欠肇庆中恒制药欠付款本金 388,000,000.00 元以及对应 期间内欠付款本金的利息。 更正后： 目前，肇庆高新区土储中心累计支付收储补偿价款及欠付款本金的利息共计 433,508,531.20 元，其尚欠肇庆中恒制药欠付款本金 391,000,000.00 元以及对应 1 期间内欠付款本金的利息。 广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）分别 于 2025 年 7 月 2 日、2025 年 10 月 10 日披露了《广西梧州中恒集团股份有限公 司关于政府收储控股孙公司土地的进展公告》（公告编号：临 2025-62、临 ...

Financial Performance - The company's operating revenue for the third quarter was ¥497,081,271.12, a decrease of 3.65% compared to the same period last year[4] - The total profit for the third quarter was -¥16,674,934.43, with a year-to-date profit of ¥11,059,706.30, reflecting a significant increase of 1,266.89% year-on-year[4] - The net profit attributable to shareholders for the third quarter was -¥2,437,249.27, while the year-to-date net profit was ¥24,640,374.94, an increase of 119.61% compared to the previous year[4] - The basic and diluted earnings per share for the third quarter were both -¥0.0008, while the year-to-date figures were ¥0.0078, showing a year-on-year increase of 136.36%[4] - Total operating revenue for the first three quarters of 2025 was CNY 1,809,411,026.87, down from CNY 2,401,872,835.33 in the same period of 2024, representing a decrease of approximately 24.6%[26] - The net profit attributable to shareholders of the parent company for the first three quarters of 2025 was CNY 24,640,374.94, compared to CNY 11,220,044.44 in 2024, showing an increase of approximately 119.5%[25] - The company reported a total profit of CNY 11,059,706.30 for the first three quarters of 2025, a significant increase from CNY 809,116.89 in the previous year[24] - The total comprehensive income for the first three quarters of 2025 was CNY 41,197,411.17, down from CNY 228,751,560.29 in 2024, indicating a decrease of about 82.0%[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥11,064,253,519.24, an increase of 0.78% from the end of the previous year[5] - The equity attributable to shareholders decreased to ¥5,799,508,176.13, down 3.71% from the previous year-end[5] - The company's total assets amounted to CNY 11,064,253,519.24, an increase from CNY 10,979,027,992.83 at the end of 2024[20] - Total liabilities as of September 30, 2025, were CNY 3,801,657,442.08, compared to CNY 3,464,282,597.71 at the end of 2024[21] - The company's equity attributable to shareholders was CNY 5,799,508,176.13, down from CNY 6,022,749,391.71 at the end of 2024[21] - Short-term borrowings increased to CNY 1,583,058,093.92 from CNY 1,304,042,585.63 year-over-year[21] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥156,396,673.89, reflecting a decrease of 135.05% compared to the same period last year[4] - Net cash flow from operating activities for the first three quarters of 2025 was -CNY 156,396,673.89, compared to CNY 446,258,897.73 in 2024, indicating a significant decline[26] - The cash and cash equivalents at the end of the period were CNY 4,009,475,304.33, up from CNY 3,458,763,556.53 in 2024, reflecting an increase of about 15.9%[27] - The company incurred a net cash outflow from investing activities of -CNY 23,674,555.79 in 2025, compared to a net inflow of CNY 613,984,380.89 in 2024[27] - The company’s total cash inflow from financing activities was CNY 1,584,881,111.98, compared to CNY 1,075,294,376.79 in 2024, marking an increase of approximately 47.3%[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 118,959[11] - Guangxi Investment Group Co., Ltd. holds 859,343,587 shares, accounting for 26.89% of total shares[11] - The company plans to repurchase shares at a price not exceeding RMB 3.80 per share, with a total repurchase amount between RMB 300 million and RMB 500 million[13] - As of August 25, 2025, the company completed the repurchase of 118,117,197 shares, representing 3.5649% of the total share capital, with a total expenditure of RMB 301,021,106.92[14] Product Development and Market Position - The company’s subsidiary received a total of RMB 10,365,548.61 in compensation from the Zhaoqing High-tech Zone Land Reserve Center during the first three quarters of 2025[16] - The company’s subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., received approval for a supplementary application for an injectable drug, enhancing its market competitiveness[17] - Guangxi Zhongheng Innovation Pharmaceutical Research Co., Ltd. acquired a patent for a drug technology for treating chronic heart failure for RMB 55 million[17] - The company received drug registration certificates for two products, Nicorandil tablets (5mg) and Ketorolac tromethamine injection (1ml:30mg), enhancing its product line[18] - The company plans to expand its product offerings and enhance its market presence through new drug registrations and technology transfers[18] Accounting Standards - The new accounting standards or interpretations will be implemented starting from 2025, affecting the financial statements from the beginning of that year[28]

Core Viewpoint - Zhongheng Group's subsidiary, Laimei Pharmaceutical, is participating in the 11th batch of national centralized drug procurement and aims to be selected for the procurement of Nicorandil tablets, which have not yet commenced sales [1] Group 1 - The potential selection for procurement could enhance product sales and market expansion for the company [1] - Successful procurement and contract signing would positively impact the company's brand influence and long-term development [1] - There are uncertainties regarding the bidding results and contract signing, and various factors affect drug production and sales [1]

Group 1 - The core point of the article is that Zhongheng Group reported a decline in revenue for the third quarter while showing growth in the first three quarters of the year [1] Group 2 - In the third quarter, the company's revenue was 497 million yuan, a year-on-year decrease of 3.65% [1] - The net profit for the third quarter was a loss of 2.4372 million yuan [1] - For the first three quarters, the company's revenue reached 1.948 billion yuan, reflecting a year-on-year increase of 1.10% [1] - The net profit for the first three quarters was 24.6404 million yuan, representing a year-on-year growth of 119.61% [1]

Core Viewpoint - Zhongheng Group's stock price has shown fluctuations, with a year-to-date increase of 13.82% and a recent decline over the past 20 days [1] Financial Performance - For the first half of 2025, Zhongheng Group reported revenue of 1.451 billion yuan, a year-on-year increase of 2.84%, and a net profit attributable to shareholders of 27.08 million yuan, up 23.59% year-on-year [2] - Cumulative cash dividends since the A-share listing amount to 2.941 billion yuan, with 68.74 million yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 6.05% to 114,900, while the average circulating shares per person increased by 5.14% to 28,742 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Southern CSI 1000 ETF, with both increasing their holdings compared to the previous period [3] Market Activity - On October 24, Zhongheng Group's stock fell by 2.10%, trading at 2.80 yuan per share, with a total market capitalization of 8.947 billion yuan [1] - The stock experienced a net outflow of 468,100 yuan in principal funds, with significant buying and selling activity from large orders [1]

Core Viewpoint - Guangxi Wuzhou Zhongheng Group Co., Ltd. has successfully transformed from a traditional pharmaceutical company to a technology-driven enterprise during the "14th Five-Year Plan" period, focusing on innovation and research and development in traditional Chinese medicine and chemical drugs [1][2]. Innovation in Pharmaceuticals - Zhongheng Group has made significant strides in innovative drugs, particularly with the "Sanqi Granules," which received clinical trial approval from the National Medical Products Administration, targeting chronic kidney disease [2][3]. - The market for chronic kidney disease in China is substantial, with approximately 150 million patients and a market size exceeding 32 billion yuan, indicating a significant opportunity for the company [2]. Product Development and Brand Value - The company has been actively involved in the secondary development of core products, with the "Zhonghua Die Da Wan" being recognized as one of the "China's 500 Most Valuable Brands," valued at over 10 billion yuan [3]. - Zhongheng Group is expanding into cardiovascular disease treatments, with a new innovative drug targeting chronic heart failure, addressing a market with over 12 million patients in China [3]. Research and Development Investment - From 2021 to 2024, Zhongheng Group invested nearly 687 million yuan in R&D, accounting for 6.11% of its revenue, establishing a robust research funding mechanism [5]. - The company has formed partnerships with national key laboratories and universities to enhance its research capabilities and facilitate the transition from research to industry [5]. Smart Manufacturing and Technology Integration - Zhongheng Group has integrated modern technology into its manufacturing processes, significantly improving production efficiency, with the solid preparation workshop achieving a production rate of 1,000 pills per minute [6]. - The company holds 343 valid patents and has received multiple awards for its innovations, showcasing its commitment to modernizing traditional practices [6]. Brand Expansion and Market Reach - The company has successfully modernized its product offerings, such as the "Guilinggao," which has evolved from a traditional dessert to a health food product, now available in various convenient packaging [7][8]. - Zhongheng Group's brands have entered high-end retail markets and expanded online, contributing to a combined brand value exceeding 40 billion yuan during the "14th Five-Year Plan" [9].

Core Insights - Zhongheng Group has achieved significant milestones in the field of traditional Chinese medicine innovation, including the establishment of the "ASEAN Traditional Chinese Medicine Research Center" in collaboration with Shanghai University of Traditional Chinese Medicine, which has been recognized as a key innovation hub in Guangxi [1][2] - The company’s subsidiary, Wuzhou Pharmaceutical, has been recognized as one of the "Top 100 High-tech Enterprises in Guangxi" for two consecutive years, highlighting its innovation capabilities and industry competitiveness [1][2] Research and Development - The ASEAN Traditional Chinese Medicine Research Center focuses on key areas such as cardiovascular diseases and tumors, with a comprehensive development path that includes new drug development and secondary development of exclusive varieties [1] - Currently, 15 projects have been initiated, including three new traditional Chinese medicine drugs for treating specific conditions and one chemical drug for atopic dermatitis [1] - The center has also launched five secondary development projects for exclusive varieties, including injectable thrombolytic agents and various health products [1] Academic and Collaborative Efforts - The center has secured funding exceeding 2 million yuan through various projects, including one national key research and development project and two Guangxi natural science fund projects [2] - Collaboration with key laboratories and universities is being strengthened, with 11 experts from Shanghai University of Traditional Chinese Medicine invited to participate in projects [2] - Wuzhou Pharmaceutical has initiated over 40 research projects, including 4 national-level and 11 regional-level projects, with 25 projects successfully completed [2]

证券代码：600252 证券简称：中恒集团 公告编号：临 2025-87 广西梧州中恒集团股份有限公司 关于政府收储控股孙公司土地的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 签订上述补充协议后，公司控股孙公司肇庆中恒制药合计收到肇庆高新区土 储中心支付的欠付款本金及利息 53,324,788.20 元。 具体内容详见公司于 2024 年 1 月 3 日、2024 年 1 月 30 日、2024 年 7 月 2 日、2024 年 10 月 9 日、2025 年 1 月 3 日、2025 年 4 月 2 日、2025 年 7 月 2 日 在上海证券交易所网站（www.sse.com.cn）披露的《广西梧州中恒集团股份有限 公司关于政府收储控股孙公司土地事项进展暨签订补充协议的公告》（公告编号： 临 2024-1）及相关进展公告（公告编号：临 2024-5、临 2024-54、临 2024-84、 临 2025-3、临 2025-34、临 2025-62）。 二、土地收储的进展情况 根据肇庆中恒制药与肇庆高新区土储中 ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2025-86 公司已于 2025 年 8 月 30 日披露《广西梧州中恒集团股份有限公司 2025 年 半年度报告》及其摘要，为便于广大投资者更全面深入地了解公司 2025 年半年 度经营成果、财务状况，公司计划于 2025 年 10 月 17 日（星期五）10:00-11:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行互动交流。 一、说明会类型 广西梧州中恒集团股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 10 月 17 日（星期五）10:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com） 会议召开方式：上证路演中心网络文字互动 投资者可于 2025 年 10 月 10 日（星期五）至 10 月 16 日（星期四）16:00 ...